A Phase 1b/2 Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Advanced Breast Cancer

Full Title

A Phase Ib/II trial of Lenvatinib plus Pembrolizumab plus Fulvestrant in ER-positive/ HER2-negative Metastatic Breast Cancer

Purpose

Researchers are assessing the effectiveness of the combination of lenvatinib, pembrolizumab immunotherapy, and fulvestrant to treat advanced breast cancer. The people in this study have inoperable or metastatic breast cancer (cancer that has spread) that is estrogen receptor-positive and HER2-negative.

Lenvatinib blocks proteins that promote cancer cell growth and survival. Pembrolizumab boosts the power of the immune system to find and kill cancer cells. Fulvestrant is a hormonal therapy that decreases the amount of estrogen. It may slow or stop the growth of breast cancer cells that need estrogen to grow.

Lenvatinib is taken orally (by mouth). Pembrolizumab is given intravenously (by vein). Fulvestrant is given as an injection into the buttocks.

Contact

For more information and to see if you can join this study, please call 646-497-9064.